Methods to improve the diagnostic accuracy of malignant mesothelioma

Respiratory Medicine

Volumn 90, Issue 4, 1996, Pages 191-199

  Dejmek, A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; HYALURONIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY BEREP 4; SCLEROPROTEIN; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; HISTOCHEMISTRY; HUMAN; IMMUNOCYTOCHEMISTRY; INTERMEDIATE FILAMENT; MALIGNANT MESOTHELIOMA; MEDICOLEGAL ASPECT; NEEDLE BIOPSY; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; THORACOSCOPY;

EID: 0029877283     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90286-3     Document Type: Review

References (129)

1. Enzinger FM, Weiss SW. Soft Tissue Tumors. St Louis: The CV Mosby Company, 1988, pp. 689-706.
2. Sridhar KS, Doria R, Raub WA, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70: 2969-2979.
3. Lewis RJ, Sisler GE, Mackenzie JW. Diffuse, mixed malignant pleural mesothelioma. Ann Thorac Surg 1981; 31: 53-60.
4. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 1993; 72: 389-393.
5. Edge J-R, Choudhury SL. Malignant mesothelioma of the pleura in Barrow in Furness. Thorax 1978; 33: 26-30.
6. Suzuki Y, Pathology of human malignant mesothelioma. Semin Oncol 1980; 8: 268-282.
7. Churg A, Golden J. Current problems in pathology of asbestos-related disease. Pathol Ann 1982; 17(2): 33-66.
8. Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life-a practical approach. J Pathol 1984; 143: 147-175.
9. Whitaker D, Shilkin KB. The cytology of malignant mesothelioma in Western Australia. Acta Cytol 1978; 22: 67-70.
10. Tao LC. The cytopathology of mesothelioma. Acta Cytol 1979; 23: 209-213.
11. Kwee WS, Veldhuisen RW, Golding RP, Alons CA, Morewetz F, Boon ME. Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid. Acta Cytol 1982; 26: 401-406.
12. Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey Community Hospital. Acta Cytol 1984; 28(1): 37-45.
13. Van Gelder T, Hoogsteden HC, van Hezik EJ, Vandenbroucke JP, Planbeydt HT. Malignant pleural mesothelioma in the southwestern part of the Netherlands. Eur Respir J 1989; 2: 981-984.
14. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelial and biphasic pleural mesothelioma. Arch Pathol Lab Med 1990; 114: 845-851.
15. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-1168.
16. Elmes PC, Simpson JCM. The clinical aspects of mesothelioma. Q J Med 1976; 69: 427-449.
17. Hulks G, Thomas JSTJ, Waclawski E. Malignant pleural mesothelioma in Western Glasgow 1980-6. Thorax 1989; 44: 496-500.
18. Di Bonito L, Falconieri G. Cytopathology of malignant mesothelioma. A study of its patterns and histological bases. Diagn Cytopathology 1993; 9: 25-31.
19. Stevens MW, Leong AS-Y, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma: A stepwise logistic regression analysis. Diagn Cytopathol 1992; 8: 333-341.
20. Warhol MJ, Hickey WF, Corson JM. Malignant mesothelioma: Ultrastructural distinction from adenocarcinoma. Am J Surg Pathol 1982; 6: 307-314.
21. Mather J, Stanbridge CM, Butler EB. Method for the removal of selected cells from cytological smear preparations for transmission electron microscopy. J Clin Path 1981; 34: 1355-1357.
22. Bedrossian CWM. Malignant Effusions. A Multimodal Approach to Cytologic Diagnosis. Tokyo: Igako-Shoin, Medical Publishers Inc, 1994, pp. 101-119.
23. Bolen JW, Thorning D. Mesotheliomas: a light and electronmicroscopical study concerning histogenetic relationships between the epithelial and the mesenchymal variants. Am J Surg Pathol 1980; 4: 451-464.
24. Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol 1986; 10(1): 34-47.
25. Burns TR, Greenberg D, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer 1985; 56: 2036-2040.
26. Jones JSP (ed) Pathology of the Mesothelium. Berlin: Springer Verlag, 1987.
27. Kahn HJ, Hanna W, Yeger H, Baumal R. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy. Am J Pathol 1982; 109: 206-214.
28. Dewar A. Valente M, Ring NP. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: An ultrastructural and cytochemical comparison. J Pathol 1987; 152: 309-316.
29. Leong AS-Y, Stevens MW, Mukherjee TM. Malignant mesothelioma: Cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation. Sem Diagn Pathol 1992; 9: 141-150.
30. Scott JE, Dorling J. Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions. Histochemie 1965; 5: 221-233.
31. Arai H, Endo M, Sasai Y et al. Histochemical demonstration of hyaluronic acid in a case of pleural mesothelioma. Am Rev Resp Dis 1975; 111: 699-702.
32. Yamaha K. The effect of digestion with Streptomyces hyaluronidase upon certain histochemical reactions of hyaluronic acid containing tissues. J Histochem Cytochem 1973; 21: 794-803.
33. Roggli WL: Kolbeck J, Sanfilippo F. Pathology of human mesothelioma. Etiologic and diagnostic considerations. Pathol Annu 1987; 22(2): 91-131.
34. Wagner JC, Munday DE, Harrington JS. Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J Pathol Bacterial 1962; 84: 73-78.
35. Fisher ER, Hellstrom R. The periodic acid-Schiff reaction as an aid in the identification of mesothelioma. Cancer 1960; 13: 837-841.
36. Kannerstein M, Churg J, Magner D. Histochemical studies in the diagnosis of mesothelioma. In: Bogovski P, ed. Biological Effects of Asbestos. Lyons: IARC, 1973, pp. 62-64.
37. Greenberg SD. Asbestos lung disease. Semin Resp Med 1982; 4: 130-137.
38. Wang N-S, Huang S-N, Gold P. Absence of carcino-embryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers. Cancer 1979; 44: 937-943.
39. Marshall RJ, Herbert A, Braye SG, Jones DB, Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium. J Clin Pathol 1984; 37: 1215-1221.
40. Lucas JG, Tuttle SE. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma. J Surg Oncol 1987; 35: 30-34.
41. Strickler JG, Herndier BG, Rouse RV. Immunohistochemical staining in malignant mesothelioma. Am J Clin Pathol 1987; 88: 610-614.
42. Corson JM, Pinkus GS. Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen. An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982; 108: 80-87.
43. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 1984; 8: 277-279.
44. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathol 1984; 8: 793-803.
45. Battifora H, Kospinski MI. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Cancer 1985; 55: 1679-1685.
46. Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am J Surg Pathol 1987; 11(6): 445-456.
47. Pfaltz M, Odermatt B, Christen B, Ruettner JR. Immunohistochemistry in the diagnosis of malignant mesothelioma. Virchows Arch A 1987; 411: 387-393.
48. Tron V, Wright JL, Churg A. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Arch Pathol Lab Med 1987; 11: 291-293.
49. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986; 123: 212-219.
50. Ghosh AK, Gatter KC, Dunnill MS, Mason DY. Immunohistological staining of reactive mesothelium, mesothelioma and lung adenocarcinoma with a panel of monoclonal antibodies. J Clin Pathol 1987; 40: 19-25.
51. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989; 13: 276-291.
52. Heckmayr M, Gatzemeier U, Niendorf A, Fasske E, Schröder S. Leu-M1, CEA und intermediärfilamentproteine in der immunologischen Differentialdiagnose maligner Pleuramesotheliom. TumorDiagn u Therapie 1990; 11(2): 74-78 (in German).
53. Soosay GN, Griffiths M, Papadaki L, Happerfield L, Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Pathol 1991; 163: 299-305.
54. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesotheloma. Cancer 1994; 73: 464-469.
55. Said JW, Nash G, Banks-Schlegel S, Sassoon AF, Murakami S, Shintaku IP. Keratin in human lung tumors. Patterns of localization of different-molecular-weight keratin proteins. Am J Pathol 1983; 113: 27-32.
56. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalogue of human cytokeratin polypeptides: Patterns of expression of specific cytokeratins in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
57. Popper H, Wirnsberger G, Hoefler H, Denk H. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas. Cancer Detect Prevent 1987; 10: 167-174.
58. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985; 121: 235-247.
59. Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch 1989; 58: 129-145.
60. Waltz AE, Said JW, Shintaku P, Sassoon AF, Banks-Schlegel S. Keratins of different molecular weight in exfoliated mesothelial and adenocarcinoma cells - An aid to cell identification. Am J Clin Pathol 1984; 81: 442-446.
61. Mayall FG, Goddard H, Gibbs AR. The diagnostic implications of variable cytokeratin expression in mesotheliomas. J Pathol 1993; 170: 165-168.
62. Upton MP, Hirohashi S, Tome Y, Miyazawa H, Suemasu K, Himosato Y. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986; 10: 560-567.
63. Jasani B, Edwards RE, Thomas ND, Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch (Pathol Anat) 1985; 406: 441-448.
64. Raymond WA, Leong AS-Y. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol 1989; 157: 299-306.
65. McNutt MA, Bolen JW, Gown AM, Hammar SP, Vogel AM. Co-expression of intermediate filaments in human epithelial neoplasms. Ultrastruct Pathol 1985; 9: 31-43.
66. Ramaekers FCS, Haag D, Kant A, Moesker O, Jap PHK, Vooijs GP. Coexpression of keratin- and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 1983; 80: 2618-2622.
67. Azumi N, Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol 1987; 88: 286-296.
68. Truong LD, Rangdaeng S, Cagle P, Ro JY,. Hawkins H, Font RL. The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 1990; 93: 305-314.
69. Heyderman E, Strudley I, Powell G, Richardson TC, Cordell JL, Mason DY. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2. Br J Cancer 1985; 52: 355-361.
70. Pinkus GS, Kurtin PJ. Epithelial membrane antigen: A diagnostic discriminant in surgical pathology: Immunohistochemical profile in epithelial, mesenchymal and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 1985; 16: 929-940.
71. Van der Kwast TH, Versnel MA, Delahaye M, De Jong A, Zondervan PE, Hoogsteden H. Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study. Acta Cytol 1988; 32(2); 169-174.
72. Leong AS-Y, Parkinson R, Milios J. Thick cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990; 6: 9-13.
73. Epenetos AA, Canti G, Taylor-Papadimitriou J, Curling M, Bodmer WF. Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet 1982; 2: 1004-1006.
74. Mason MR, Bedrossian CWM, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987; 3: 215-221.
75. Esteban JM, Yokota S, Husain S, Battifora H. Immunocytochemical profile of benign and carcinomatous effusions. Am J Clin Pathol 1990; 94: 698-705.
76. Nance KV, Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Clin Pathol 1991; 95: 867-874.
77. Ghosh AK, Spriggs AI, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol 1983; 36: 1154-1164.
78. To A, Dearnaley D, Ormerod MG, Canti G, Coleman DV. Epithelial membrane antigen. Its use in the cytodiagnosis of malignancy in serous effusions. Am J Clin Pathol 1982; 78: 214-219.
79. Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol 1986; 10: 227-236.
80. Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991; 67: 655-662.
81. Szpak CA, Johnston WW, Roggli V et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody B72.3. Am J Pathol 1986; 122: 252-260.
82. Latza U, Niedobitek G, Schwartin R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. Am J Clin Pathol 1990; 43: 213-219.
83. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991; 15: 779-784.
84. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992; 16: 593-599.
85. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: An immunocytochemical study of 232 cases. Diagn Cytopathol 1993; 9: 516-521.
86. Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies. Acta Cytol 1993; 37: 439-447.
87. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994; 10: 130-134.
88. Kataoka H, Wikström B, Klominek J, Gay RE, Gay S, Hjerpe A. Immunocytochemical demonstration of collagen types I and IV in cells isolated from malignant mesothelioma and in lung cancer cell lines. Lung Cancer 1990; 6: 16-27.
89. Kallianpur AR, Carstens PHB, Liotta LA, Frey KP, Siegal GP. Immunoreactivity in malignant mesotheliomas with antibodies to basement membrane components. Mod Pathol 1990; 3: 11-18.
90. Ashall F, Bramwell ME, Harris H. A new marker for human cancer cells. The ca antigen and the ca 1 antibody. Lancet 1982; ii: 1-6.
91. McGee JO'D, Woods JC, Ashall B, Bramwell ME, Harris H. A new marker for human cancer cells 2. Immunohistochemical detection of the ca antigen in human tissues with the cal antibody. Lancet 1982; ii: 7-10.
92. Woods JC, Spriggs AI, Harris H, McGee JO'D. A new marker for human cancer cells 3. Immunocytochemical detection of malignant cells in serous fluids with the cal antibody. Lancet 1982; ii: 511-513.
93. Burnett RA, Deery ARS, Adamson MR, Liddle C, Thomas M, Roberts GR. Evaluation of Ca 1 antibody in pleural biopsy tissue. Lancet 1983; i: 1158.
94. Pallesen G, Jepsen FL, Hastrap J, Ipsen A, Hvidberg N. Experience with the Oxford tumour marker (Ca 1) in serous effusions. Lancet 1983; i: 1326.
95. Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985; 40: 91-95.
96. Spurr NK, Durbin H, Sheer D, Parker M, Bobrow L, Bodmer WF. Characterisation and chromosomal assignment of human cell surface antigen defined by the monoclonal antibody AUA1. Int J Cancer 1986; 38: 631-636.
97. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao M-S, Pastan I, Willingham MC. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16: 259-268.
98. Kondi-Paphitis A, Addis BJ. Secretory component in pulmonary adenocarcinoma and mesothelioma. Histopathology 1986; 10: 1279-1287.
99. Mayall FG, Jasani B, Gibbs AR. Immunohistochemical positivity for neuron-specific enolase and Leu-7 in malignant mesotheliomas. J Pathol 1991; 165: 325-328.
100. Rasmussen OO, Larsen KE. S-100 protein in malignant mesotheliomas. Arch Pathol Microbiol Immunol Scand (A) 1985; 93: 199-201.
101. Herbert A, Gallagher PJ. Interpretation of pleural biopsy specimens and aspirates with the immunoperoxidase technique. Thorax 1982; 37: 822-827.
102. Permatter W, Wiesinger H. Immunohistochemical study of lysozyme, alphal-chymotrypsin, tissue polypeptide antigen, keratin and carcinoembryonic antigen in effusion sediments. Acta Cytol 1987; 31: 104-112.
103. Singh G, Whiteside TL, Dekker MD. Immunodiagnosis of mesothelioma. Use of antimesothelial cell serum in an indirect immunofluorescence assay. Cancer 1979; 43: 2288-2296.
104. Donna A, Betta PG, Bellingeri D, Marchesini A. New marker for mesothelioma: an immunoperoxidase study. J Clin Pathol 1986; 39: 961-968.
105. Donna A, Betta PG, Robutti F. Use of antimesothelial cell antibody and computer-assisted quantitative analysis for distinguishing between reactive and neoplastic serosal tissues. J Clin Pathol 1987; 40: 1428-1431.
106. Donna A, Betta PG, Jones JSP. Verification of the histological diagnosis of malignant mesothelioma in relation to the binding of an anti-mesothelial cell antibody. Cancer 1989; 63: 1331-1336.
107. Donna A, Betta PG, Bellingeri D, Tallarida F, Pavesi M, Pastormerlo M. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody. Diagn Cytopathol 1992; 8: 361-365.
108. Collins CL, Schaefer R, Cook CD et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Eur Respir Rev 1993; 3(11): 59-60.
109. O'Hara CJ, Corson JM, Pinkus GS, Stahel RA. ME1. A monoclonal antibody that distinguishes epithelial-type mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990; 136: 421-428.
110. Skov BG, Lauritzen AF, Hirsch F, Nielsen HW. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis. Histopathol 1994; 24: 553-557.
111. Szpak CA, Johnston WW, Lottich SC, Kufe D, Thor A, Schlom J. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) will cells in malignant and benign effusions. Acta Cytol 1984; 28: 356-367.
112. Van der Kwast TH, Delahaye M, Versnel M, Hoogstenden H. Improvement of the cytological diagnosis of malignant mesothelioma. Eur Respir Rev 1993; 3(11): 57-58.
113. Guzman J, Bross KJ, Wuertemberger G, Costabel U. Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets. Chest 1989; 95: 590-595.
114. Frisman DM, McCarthy WF, Schleiff P, Buckner S-B, Nocito JD, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: Use of logistic regression analysis to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993; 6: 179-184.
115. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 1994; 102: 255-264.
116. Waxler B, Eisenstein R, Battifora H. Electrophoresis of tissue glycosaminoglycans as an aid in the diagnosis of mesotheliomas. Cancer 1979; 4: 221-227.
117. Chiu B, Churg A, Tengbland A, Pearce R, McCaughey TE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984; 54: 2195-2199.
118. Boersma A, Degand P, Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Resp 1980; 16: 41-45.
119. Pettersson MD, Fröseth B, Riska H, Klockars M. Concentration of hyalouronic acid in pleura fluid as a diagnostic aid for malignant mesothelioma. Chest 1994; 5: 1037-1039.
120. Ebert W, Stabrey A, Sibinger M, Schrenk M. Value of pleural fluid hyaluronic acid and carcinoembryonic antigen determinations in the differential diagnosis between malignant mesothelioma and pleuritis carcinomatosa. TumorDiag u Therapie 1991; 12: 1-6 (in German).
121. Hillerdal G, Lindquist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer 1991; 7: 2410-2414.
122. Mårtensson G, Thylén A, Lindqvist U, Hjerpe A. The sensitivity of hyalouronan analysis of pleural fluid in malignant mesothelioma and a comparison of different methods. Eur Resp Rev 1993; 3: 55-56.
123. Sundblad L. Studies on hyalouronic acid in synovial fluids. Acta Soc Med Ups 1958; 58: 135-141.
124. Tengblad A. Quantitative analysis of hyaluronate in nanogram amounts. Biochem J 1980; 185: 101-105.
125. Laurent UBG, Tengblad A. Determination of hyaluronate in biological samples by a specific radioassay. Acta Biochem 1980; 109: 386-394.
126. Brandt R, Hedlöf E, Åsman I, Bucht H, Tengblad A. A convenient radiometric assay for hyaluronan. Acta Otolaryngol (Stockholm) 1987; 442: 31-35.
127. Hjerpe A, Antonopoulos CA, Engfeldt B. The determination of hyaluronic acid using high performance liquid chromatography. J Chromatogr 1982; 245: 365-368.
128. Hjerpe A. Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin Chem 1986; 32: 952-956.
129. Nurminen M, Dejmek A, Mårtensson G, Thylén A, Hjerpe A. Clinical utility of liquid chromatographic analysis of effusions for hyalouronate content. Clin Chem 1994; 40: 777-780.